MDT-AP-1256
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 108
- os_event
- false
- age_years
- 1
- sex
- M
- new_clusters
- S3
- umap1_2d
- -1.267405097
- umap2_2d
- -7.129966452
- umap1_3d
- -3.402848319
- umap2_3d
- -3.233649498
- umap3_3d
- 6.625991456
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.490
- ANGIOGENESIS+0.480
- ALLOGRAFT_REJECTION+0.390
- COMPLEMENT+0.380
- INFLAMMATORY_RESPONSE+0.360
- CHOLESTEROL_HOMEOSTASIS+0.350
- MTORC1_SIGNALING+0.350
- HYPOXIA+0.340
- FATTY_ACID_METABOLISM+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.120
- SPERMATOGENESIS-0.120
- HEME_METABOLISM-0.110
- KRAS_SIGNALING_DN-0.100
- PROTEIN_SECRETION-0.100
- BILE_ACID_METABOLISM-0.040
- WNT_BETA_CATENIN_SIGNALING+0.000
- TGF_BETA_SIGNALING+0.010
- DNA_REPAIR+0.050
- E2F_TARGETS+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2149 | Med | Medulloblastoma | 0.918 |
| 2 | TCGA-BH-A0DZ-01A-11R-A00Z-07 | — | C | 0.887 |
| 3 | MDT-AP-0545 | Med | Medulloblastoma | 0.884 |
| 4 | TCGA-38-4629-01A-02R-1206-07 | — | cohortA1 | 0.883 |
| 5 | EPT0508 | EPN | Posterior Fossa EPN | 0.882 |
| 6 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.882 |
| 7 | 61496AD6-7265-4D58-87CC-4FEE9723106E | — | — | 0.878 |
| 8 | 20060039.TNBC | — | C | 0.877 |
| 9 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.873 |
| 10 | MNG919 | — | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |